Bovine Tuberculosis Diagnosis Market by Test Type (Caudal Fold Test, Elisa, Gamma Interferon Assay), Product (Instruments, Kits, Reagents), End User - Global Forecast 2025-2032
Description
The Bovine Tuberculosis Diagnosis Market was valued at USD 887.85 million in 2024 and is projected to grow to USD 960.80 million in 2025, with a CAGR of 8.03%, reaching USD 1,648.16 million by 2032.
Comprehensive Overview of Bovine Tuberculosis Diagnostic Landscape Spotlighting Industry Challenges and Emerging Opportunities in Livestock Health
The agricultural sector’s economic viability and global food security are inextricably linked to controlling infectious diseases in livestock. Bovine tuberculosis remains one of the most challenging zoonotic diseases, impacting herd productivity and trade. As stakeholders seek more reliable diagnostic solutions, the marketplace has witnessed significant innovation in both traditional and molecular assays.
Regulatory bodies worldwide are intensifying surveillance requirements, compelling producers and veterinary services to adopt more sophisticated diagnostic protocols. In parallel, emerging technologies promise to deliver faster turnaround times and higher sensitivity, reshaping how disease monitoring programs are structured. Consequently, organizations must understand these parallel trends to align investments with both regulatory compliance and operational efficiency.
This executive summary offers a concise but thorough introduction to the evolving diagnostic landscape for bovine tuberculosis. It establishes the context for subsequent sections by highlighting current testing methodologies, regulatory pressures, and technology-driven improvements. The ensuing analysis will equip decision-makers with a balanced perspective on critical market dynamics, enabling informed strategic planning.
Exploring the Technological and Policy-Driven Revolution Redefining Bovine Tuberculosis Detection and Surveillance Practices
Over the past decade, the bovine tuberculosis diagnostic arena has undergone transformative shifts driven by technological breakthroughs and shifting policy frameworks. Traditional skin testing methods have been supplemented by sophisticated serological assays and molecular diagnostics, enabling earlier detection and more accurate disease management. At the same time, digital data platforms have begun to streamline case reporting and field surveillance, fostering greater collaboration across public health and veterinary networks.
Regulatory incentives have also evolved, prioritizing evidence-based approaches and traceability. Incentive programs now often link funding to the adoption of higher-accuracy assays, fostering a market environment that rewards innovation. Moreover, cross-sector alliances between pharmaceutical firms, device manufacturers, and research institutes have accelerated product development cycles, blurring the lines between siloed disciplines.
These shifts have collectively redefined the value proposition of diagnostic providers, driving competition around assay sensitivity, speed, and integration with herd management systems. As a result, decision-makers must navigate a more complex ecosystem where strategic partnerships and technology interoperability are as critical as assay performance.
Analyzing the Far-Reaching Effects of the 2025 Tariff Regime on Supply Chains and Procurement Strategies for Tuberculosis Diagnostics
With the introduction of a comprehensive tariff framework in 2025, diagnostic kit imports into the United States experienced significant cost realignments. Procurement budgets faced upward pressure as duties were applied to a broad range of assay components, including specialized antigens and molecular reagents. This policy shift prompted distributors and end users alike to reevaluate supply chain strategies.
In response, several diagnostic manufacturers accelerated domestic sourcing of raw materials and consolidated global production footprints to mitigate margin erosion. Meanwhile, government agencies and research institutes began to explore public-private partnerships aimed at localizing reagent manufacturing and equipment assembly. These collaborations not only addressed tariff challenges but also enhanced resilience against logistical disruptions.
End users, particularly veterinary hospitals and diagnostic laboratories, have confronted higher acquisition costs and extended lead times. However, many have leveraged bulk procurement consortia and long-term supply contracts to stabilize pricing. As these strategic adaptations become entrenched, the market outlook has shifted toward exploring regional manufacturing hubs and fostering collaborative networks to ensure sustainable access to critical diagnostic tools.
Holistic Dissection of Diagnostic Modalities, Product Categories, and End User Adoption Patterns Shaping Market Trajectories
In-depth examination of diagnostic approaches reveals that skin-based testing remains foundational, with the caudal fold test-encompassing both comparative intradermal and single intradermal cervical methods-serving as a frontline screen. Yet serological assays such as ELISA and cell-mediated immunity assessments via gamma interferon are gaining traction for their higher specificity. At the same time, polymerase chain reaction techniques provide definitive confirmation by detecting mycobacterial DNA.
On the product front, diagnostic laboratories are investing in sophisticated instruments, including ELISA readers and PCR machines, to support multiplexed workflows. The demand for ready-to-use test kits spans from caudal fold test kits to ELISA, gamma interferon, and PCR kits, each tailored to distinct diagnostic pathways. Reagents remain a critical component, encompassing purified antigens for skin tests, specialized enzymes for amplification protocols, and primers and probes designed to target Mycobacterium bovis with precision.
End users vary in their adoption profiles. Diagnostic laboratories leverage high-throughput platforms to process large sample volumes, while government agencies prioritize assays that align with national eradication objectives. Research institutes adopt cutting-edge molecular assays for epidemiological studies, and veterinary hospitals focus on rapid, point-of-care options to guide herd management decisions. Together, these segmentation insights illuminate areas of unmet need and potential growth as stakeholders seek to integrate complementary diagnostic modalities.
Regional Differentiation of Diagnostic Practices and Regulatory Drivers Informing Tailored Market Engagement Strategies
Regional nuances significantly influence diagnostic preferences and deployment strategies. In the Americas, public health agencies have championed skin testing for cattle populations, supported by cost-sharing programs that incentivize standardized surveillance. However, private veterinary networks are increasingly incorporating ELISA and PCR workflows to accelerate herd turnover decisions in commercial operations.
Europe, the Middle East, and Africa present a tapestry of regulatory environments and resource availability. While European Union directives mandate rigorous confirmatory testing, resource constraints in parts of Africa and the Middle East have led to reliance on rapid field assays. Cross-border collaborations, notably between research consortia and government bodies, have facilitated technology transfer and localized capacity building.
In the Asia-Pacific region, rising demand for high-value dairy and beef exports has spurred investments in molecular diagnostics. National eradication initiatives in Oceania and Southeast Asia have driven coordinated adoption of gamma interferon assays alongside traditional skin tests. These regional dynamics underscore the importance of tailoring diagnostic portfolios and service models to diverse regulatory landscapes and economic contexts.
Profiling Market Leaders and Collaborative Ecosystem Strategies Driving Innovation and Competitive Differentiation
Leading life science corporations and specialized diagnostics firms are intensifying efforts to expand their presence in the bovine tuberculosis space. Multinational players renowned for robust R&D pipelines are introducing next-generation PCR platforms optimized for field deployment, while niche developers are focusing on high-throughput ELISA systems with enhanced automation features. Strategic alliances between reagent suppliers and instrument manufacturers are proliferating to offer bundled solutions that simplify buyer decisions.
Partnerships with academic and government laboratories are also a focal point, as collaborative validation studies lend credence to new assay claims and support regulatory approvals. Moreover, mergers and acquisitions continue to reshape the competitive landscape, with established companies acquiring innovative start-ups to gain proprietary antigen libraries and streamlined manufacturing processes.
On the service side, contract research and veterinary networks are differentiating through value-added services such as digital disease mapping and predictive analytics. These offerings not only reinforce customer loyalty but also generate recurring revenue streams that complement core diagnostic sales. As companies vie for leadership, the emphasis on integrated solutions and ecosystem engagements is becoming increasingly pronounced.
Strategic Pathways for Diagnostic Providers to Strengthen Technological Synergies, Regulatory Alignment, and Market Penetration
To capitalize on the evolving bovine tuberculosis diagnostic field, industry leaders should prioritize partnerships that enhance technology integration across platforms. Cultivating alliances with reagent innovators can accelerate the development of multiplex assays, while collaboration with data analytics providers can unlock predictive surveillance capabilities. Simultaneously, investing in localized manufacturing and distribution networks will mitigate the impact of geopolitical and tariff uncertainties.
Engagement with regulatory agencies early in the development cycle is critical to streamline approvals and align products with emerging compliance requirements. Companies should also pursue real-world evidence studies to demonstrate assay performance in diverse herd management scenarios. Such evidence can bolster credibility with both public sector purchasers and private veterinary clients.
Finally, differentiated service offerings-ranging from remote diagnostic support to end-to-end sample logistics-will distinguish leading providers. By adopting a customer-centric approach that addresses operational pain points, organizations can foster deeper market penetration and longer-term revenue visibility.
Comprehensive Multi-Tiered Research Approach Integrating Secondary Analysis and Stakeholder Interviews for Unbiased Insights
Our research foundation integrates extensive secondary research, including the review of scientific literature, regulatory filings, and industry publications. Complementing this, primary research was conducted through interviews with key stakeholders such as laboratory directors, regulatory experts, and veterinary health professionals across major regions. Responses were triangulated to ensure consistency and to validate emerging trends.
Data collection processes adhered to rigorous quality assurance protocols, encompassing multi-round feedback loops and cross-verification against proprietary databases. Market mapping techniques identified the leading assay platforms, reagent portfolios, and service models, while scenario analysis explored the implications of policy changes and technological advancements.
The result is a robust, transparent methodology that underpins the report’s insights, providing stakeholders with dependable intelligence to guide strategic decisions in the dynamic bovine tuberculosis diagnostic landscape.
Synthesized Perspective on Market Evolution and Strategic Imperatives for Effective Bovine Tuberculosis Control Programs
As the bovine tuberculosis diagnostic market continues to evolve, stakeholders must navigate an increasingly complex ecosystem of assay technologies, regulatory frameworks, and supply chain dynamics. Advances in molecular diagnostics and digital surveillance are redefining best practices, while policy shifts such as the 2025 tariff regime underscore the need for agile operational strategies.
By understanding segmentation nuances-from traditional skin tests to cutting-edge molecular platforms-and by tailoring solutions to region-specific requirements, organizations can achieve healthier herds and more resilient commerce channels. Moreover, strategic partnerships and localized manufacturing initiatives will prove instrumental in mitigating external risks and capturing emerging growth opportunities.
In conclusion, success in this sector demands a balanced focus on innovation, regulatory engagement, and customer-centric service models. The insights presented herein provide a roadmap for leaders seeking to strengthen their competitive positioning and drive sustainable outcomes in the ongoing battle against bovine tuberculosis.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Test Type
Caudal Fold Test
Comparative Intradermal Cervical Test
Single Intradermal Cervical Test
Elisa
Gamma Interferon Assay
PCR
Product
Instruments
Elisa Readers
Pcr Machines
Kits
Caudal Fold Test Kits
Elisa Kits
Gamma Interferon Assay Kits
PCR Kits
Reagents
Antigens
Enzymes
Primers And Probes
Primers
Probes
End User
Diagnostic Laboratories
Government Agencies
Research Institutes
Veterinary Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Thermo Fisher Scientific Inc.
Zoetis Inc.
IDEXX Laboratories, Inc.
Bio-Rad Laboratories, Inc.
Merck & Co., Inc.
Neogen Corporation
HIPRA S.A.
Elanco Animal Health Incorporated
Biogal-Galed Laboratories Ltd.
VMRD, Inc.
Please Note: PDF & Excel + Online Access - 1 Year
Comprehensive Overview of Bovine Tuberculosis Diagnostic Landscape Spotlighting Industry Challenges and Emerging Opportunities in Livestock Health
The agricultural sector’s economic viability and global food security are inextricably linked to controlling infectious diseases in livestock. Bovine tuberculosis remains one of the most challenging zoonotic diseases, impacting herd productivity and trade. As stakeholders seek more reliable diagnostic solutions, the marketplace has witnessed significant innovation in both traditional and molecular assays.
Regulatory bodies worldwide are intensifying surveillance requirements, compelling producers and veterinary services to adopt more sophisticated diagnostic protocols. In parallel, emerging technologies promise to deliver faster turnaround times and higher sensitivity, reshaping how disease monitoring programs are structured. Consequently, organizations must understand these parallel trends to align investments with both regulatory compliance and operational efficiency.
This executive summary offers a concise but thorough introduction to the evolving diagnostic landscape for bovine tuberculosis. It establishes the context for subsequent sections by highlighting current testing methodologies, regulatory pressures, and technology-driven improvements. The ensuing analysis will equip decision-makers with a balanced perspective on critical market dynamics, enabling informed strategic planning.
Exploring the Technological and Policy-Driven Revolution Redefining Bovine Tuberculosis Detection and Surveillance Practices
Over the past decade, the bovine tuberculosis diagnostic arena has undergone transformative shifts driven by technological breakthroughs and shifting policy frameworks. Traditional skin testing methods have been supplemented by sophisticated serological assays and molecular diagnostics, enabling earlier detection and more accurate disease management. At the same time, digital data platforms have begun to streamline case reporting and field surveillance, fostering greater collaboration across public health and veterinary networks.
Regulatory incentives have also evolved, prioritizing evidence-based approaches and traceability. Incentive programs now often link funding to the adoption of higher-accuracy assays, fostering a market environment that rewards innovation. Moreover, cross-sector alliances between pharmaceutical firms, device manufacturers, and research institutes have accelerated product development cycles, blurring the lines between siloed disciplines.
These shifts have collectively redefined the value proposition of diagnostic providers, driving competition around assay sensitivity, speed, and integration with herd management systems. As a result, decision-makers must navigate a more complex ecosystem where strategic partnerships and technology interoperability are as critical as assay performance.
Analyzing the Far-Reaching Effects of the 2025 Tariff Regime on Supply Chains and Procurement Strategies for Tuberculosis Diagnostics
With the introduction of a comprehensive tariff framework in 2025, diagnostic kit imports into the United States experienced significant cost realignments. Procurement budgets faced upward pressure as duties were applied to a broad range of assay components, including specialized antigens and molecular reagents. This policy shift prompted distributors and end users alike to reevaluate supply chain strategies.
In response, several diagnostic manufacturers accelerated domestic sourcing of raw materials and consolidated global production footprints to mitigate margin erosion. Meanwhile, government agencies and research institutes began to explore public-private partnerships aimed at localizing reagent manufacturing and equipment assembly. These collaborations not only addressed tariff challenges but also enhanced resilience against logistical disruptions.
End users, particularly veterinary hospitals and diagnostic laboratories, have confronted higher acquisition costs and extended lead times. However, many have leveraged bulk procurement consortia and long-term supply contracts to stabilize pricing. As these strategic adaptations become entrenched, the market outlook has shifted toward exploring regional manufacturing hubs and fostering collaborative networks to ensure sustainable access to critical diagnostic tools.
Holistic Dissection of Diagnostic Modalities, Product Categories, and End User Adoption Patterns Shaping Market Trajectories
In-depth examination of diagnostic approaches reveals that skin-based testing remains foundational, with the caudal fold test-encompassing both comparative intradermal and single intradermal cervical methods-serving as a frontline screen. Yet serological assays such as ELISA and cell-mediated immunity assessments via gamma interferon are gaining traction for their higher specificity. At the same time, polymerase chain reaction techniques provide definitive confirmation by detecting mycobacterial DNA.
On the product front, diagnostic laboratories are investing in sophisticated instruments, including ELISA readers and PCR machines, to support multiplexed workflows. The demand for ready-to-use test kits spans from caudal fold test kits to ELISA, gamma interferon, and PCR kits, each tailored to distinct diagnostic pathways. Reagents remain a critical component, encompassing purified antigens for skin tests, specialized enzymes for amplification protocols, and primers and probes designed to target Mycobacterium bovis with precision.
End users vary in their adoption profiles. Diagnostic laboratories leverage high-throughput platforms to process large sample volumes, while government agencies prioritize assays that align with national eradication objectives. Research institutes adopt cutting-edge molecular assays for epidemiological studies, and veterinary hospitals focus on rapid, point-of-care options to guide herd management decisions. Together, these segmentation insights illuminate areas of unmet need and potential growth as stakeholders seek to integrate complementary diagnostic modalities.
Regional Differentiation of Diagnostic Practices and Regulatory Drivers Informing Tailored Market Engagement Strategies
Regional nuances significantly influence diagnostic preferences and deployment strategies. In the Americas, public health agencies have championed skin testing for cattle populations, supported by cost-sharing programs that incentivize standardized surveillance. However, private veterinary networks are increasingly incorporating ELISA and PCR workflows to accelerate herd turnover decisions in commercial operations.
Europe, the Middle East, and Africa present a tapestry of regulatory environments and resource availability. While European Union directives mandate rigorous confirmatory testing, resource constraints in parts of Africa and the Middle East have led to reliance on rapid field assays. Cross-border collaborations, notably between research consortia and government bodies, have facilitated technology transfer and localized capacity building.
In the Asia-Pacific region, rising demand for high-value dairy and beef exports has spurred investments in molecular diagnostics. National eradication initiatives in Oceania and Southeast Asia have driven coordinated adoption of gamma interferon assays alongside traditional skin tests. These regional dynamics underscore the importance of tailoring diagnostic portfolios and service models to diverse regulatory landscapes and economic contexts.
Profiling Market Leaders and Collaborative Ecosystem Strategies Driving Innovation and Competitive Differentiation
Leading life science corporations and specialized diagnostics firms are intensifying efforts to expand their presence in the bovine tuberculosis space. Multinational players renowned for robust R&D pipelines are introducing next-generation PCR platforms optimized for field deployment, while niche developers are focusing on high-throughput ELISA systems with enhanced automation features. Strategic alliances between reagent suppliers and instrument manufacturers are proliferating to offer bundled solutions that simplify buyer decisions.
Partnerships with academic and government laboratories are also a focal point, as collaborative validation studies lend credence to new assay claims and support regulatory approvals. Moreover, mergers and acquisitions continue to reshape the competitive landscape, with established companies acquiring innovative start-ups to gain proprietary antigen libraries and streamlined manufacturing processes.
On the service side, contract research and veterinary networks are differentiating through value-added services such as digital disease mapping and predictive analytics. These offerings not only reinforce customer loyalty but also generate recurring revenue streams that complement core diagnostic sales. As companies vie for leadership, the emphasis on integrated solutions and ecosystem engagements is becoming increasingly pronounced.
Strategic Pathways for Diagnostic Providers to Strengthen Technological Synergies, Regulatory Alignment, and Market Penetration
To capitalize on the evolving bovine tuberculosis diagnostic field, industry leaders should prioritize partnerships that enhance technology integration across platforms. Cultivating alliances with reagent innovators can accelerate the development of multiplex assays, while collaboration with data analytics providers can unlock predictive surveillance capabilities. Simultaneously, investing in localized manufacturing and distribution networks will mitigate the impact of geopolitical and tariff uncertainties.
Engagement with regulatory agencies early in the development cycle is critical to streamline approvals and align products with emerging compliance requirements. Companies should also pursue real-world evidence studies to demonstrate assay performance in diverse herd management scenarios. Such evidence can bolster credibility with both public sector purchasers and private veterinary clients.
Finally, differentiated service offerings-ranging from remote diagnostic support to end-to-end sample logistics-will distinguish leading providers. By adopting a customer-centric approach that addresses operational pain points, organizations can foster deeper market penetration and longer-term revenue visibility.
Comprehensive Multi-Tiered Research Approach Integrating Secondary Analysis and Stakeholder Interviews for Unbiased Insights
Our research foundation integrates extensive secondary research, including the review of scientific literature, regulatory filings, and industry publications. Complementing this, primary research was conducted through interviews with key stakeholders such as laboratory directors, regulatory experts, and veterinary health professionals across major regions. Responses were triangulated to ensure consistency and to validate emerging trends.
Data collection processes adhered to rigorous quality assurance protocols, encompassing multi-round feedback loops and cross-verification against proprietary databases. Market mapping techniques identified the leading assay platforms, reagent portfolios, and service models, while scenario analysis explored the implications of policy changes and technological advancements.
The result is a robust, transparent methodology that underpins the report’s insights, providing stakeholders with dependable intelligence to guide strategic decisions in the dynamic bovine tuberculosis diagnostic landscape.
Synthesized Perspective on Market Evolution and Strategic Imperatives for Effective Bovine Tuberculosis Control Programs
As the bovine tuberculosis diagnostic market continues to evolve, stakeholders must navigate an increasingly complex ecosystem of assay technologies, regulatory frameworks, and supply chain dynamics. Advances in molecular diagnostics and digital surveillance are redefining best practices, while policy shifts such as the 2025 tariff regime underscore the need for agile operational strategies.
By understanding segmentation nuances-from traditional skin tests to cutting-edge molecular platforms-and by tailoring solutions to region-specific requirements, organizations can achieve healthier herds and more resilient commerce channels. Moreover, strategic partnerships and localized manufacturing initiatives will prove instrumental in mitigating external risks and capturing emerging growth opportunities.
In conclusion, success in this sector demands a balanced focus on innovation, regulatory engagement, and customer-centric service models. The insights presented herein provide a roadmap for leaders seeking to strengthen their competitive positioning and drive sustainable outcomes in the ongoing battle against bovine tuberculosis.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Test Type
Caudal Fold Test
Comparative Intradermal Cervical Test
Single Intradermal Cervical Test
Elisa
Gamma Interferon Assay
PCR
Product
Instruments
Elisa Readers
Pcr Machines
Kits
Caudal Fold Test Kits
Elisa Kits
Gamma Interferon Assay Kits
PCR Kits
Reagents
Antigens
Enzymes
Primers And Probes
Primers
Probes
End User
Diagnostic Laboratories
Government Agencies
Research Institutes
Veterinary Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Thermo Fisher Scientific Inc.
Zoetis Inc.
IDEXX Laboratories, Inc.
Bio-Rad Laboratories, Inc.
Merck & Co., Inc.
Neogen Corporation
HIPRA S.A.
Elanco Animal Health Incorporated
Biogal-Galed Laboratories Ltd.
VMRD, Inc.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
183 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of CRISPR-Cas12a lateral flow assays for ultrasensitive on-farm btb antigen detection in high-density cattle herds
- 5.2. Integration of smartphone-enabled infrared thermographic imaging with machine learning models for early subclinical bovine tb screening in dairy operations
- 5.3. Development of multiplexed microfluidic lab-on-a-chip platforms for simultaneous detection of bovine tuberculosis and other respiratory pathogens at point of need
- 5.4. Implementation of portable real-time PCR diagnostics with lyophilized reagents for rapid confirmation of bovine tb in remote livestock trading hubs
- 5.5. Deployment of nanobody-functionalized electrochemical biosensors to enhance specificity and sensitivity in bovine tb antibody surveillance programs
- 5.6. Regulatory approval trends for novel interferon-gamma release assays and their impact on national bovine tuberculosis eradication strategies
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Bovine Tuberculosis Diagnosis Market, by Test Type
- 8.1. Caudal Fold Test
- 8.1.1. Comparative Intradermal Cervical Test
- 8.1.2. Single Intradermal Cervical Test
- 8.2. Elisa
- 8.3. Gamma Interferon Assay
- 8.4. PCR
- 9. Bovine Tuberculosis Diagnosis Market, by Product
- 9.1. Instruments
- 9.1.1. Elisa Readers
- 9.1.2. Pcr Machines
- 9.2. Kits
- 9.2.1. Caudal Fold Test Kits
- 9.2.2. Elisa Kits
- 9.2.3. Gamma Interferon Assay Kits
- 9.2.4. PCR Kits
- 9.3. Reagents
- 9.3.1. Antigens
- 9.3.2. Enzymes
- 9.3.3. Primers And Probes
- 9.3.3.1. Primers
- 9.3.3.2. Probes
- 10. Bovine Tuberculosis Diagnosis Market, by End User
- 10.1. Diagnostic Laboratories
- 10.2. Government Agencies
- 10.3. Research Institutes
- 10.4. Veterinary Hospitals
- 11. Bovine Tuberculosis Diagnosis Market, by Region
- 11.1. Americas
- 11.1.1. North America
- 11.1.2. Latin America
- 11.2. Europe, Middle East & Africa
- 11.2.1. Europe
- 11.2.2. Middle East
- 11.2.3. Africa
- 11.3. Asia-Pacific
- 12. Bovine Tuberculosis Diagnosis Market, by Group
- 12.1. ASEAN
- 12.2. GCC
- 12.3. European Union
- 12.4. BRICS
- 12.5. G7
- 12.6. NATO
- 13. Bovine Tuberculosis Diagnosis Market, by Country
- 13.1. United States
- 13.2. Canada
- 13.3. Mexico
- 13.4. Brazil
- 13.5. United Kingdom
- 13.6. Germany
- 13.7. France
- 13.8. Russia
- 13.9. Italy
- 13.10. Spain
- 13.11. China
- 13.12. India
- 13.13. Japan
- 13.14. Australia
- 13.15. South Korea
- 14. Competitive Landscape
- 14.1. Market Share Analysis, 2024
- 14.2. FPNV Positioning Matrix, 2024
- 14.3. Competitive Analysis
- 14.3.1. Thermo Fisher Scientific Inc.
- 14.3.2. Zoetis Inc.
- 14.3.3. IDEXX Laboratories, Inc.
- 14.3.4. Bio-Rad Laboratories, Inc.
- 14.3.5. Merck & Co., Inc.
- 14.3.6. Neogen Corporation
- 14.3.7. HIPRA S.A.
- 14.3.8. Elanco Animal Health Incorporated
- 14.3.9. Biogal-Galed Laboratories Ltd.
- 14.3.10. VMRD, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
